Staron A - Search Results

1

Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment.

Sanchorawala V, Barroso B, Shelton A, Goetz E, Mendelson L, Joshi T, Burke N, Sloan JM, Staron A. Sanchorawala V, et al. Among authors: staron a. Blood Adv. 2024 Nov 26;8(22):5826-5828. doi: 10.1182/bloodadvances.2024014262. Blood Adv. 2024. PMID: 39293090 Free PMC article. No abstract available.

2

Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature.

Qualls DA, Lewis GD, Sanchorawala V, Staron A. Qualls DA, et al. Among authors: staron a. Am J Transplant. 2019 Nov;19(11):3185-3190. doi: 10.1111/ajt.15499. Epub 2019 Jul 8. Am J Transplant. 2019. PMID: 31207062 Free article.

3

A new era of amyloidosis: the trends at a major US referral centre.

Staron A, Connors LH, Ruberg FL, Mendelson LM, Sanchorawala V. Staron A, et al. Amyloid. 2019 Dec;26(4):192-196. doi: 10.1080/13506129.2019.1640672. Epub 2019 Jul 15. Amyloid. 2019. PMID: 31306033

4

Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes.

Staron A, Kataria Y, Murray DL, Sloan JM, Sanchorawala V. Staron A, et al. Am J Hematol. 2020 Feb;95(2):E45-E48. doi: 10.1002/ajh.25685. Epub 2019 Nov 26. Am J Hematol. 2020. PMID: 31736101 Free article. No abstract available.

5

Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.

Staron A, Burks EJ, Lee JC, Sarosiek S, Sloan JM, Sanchorawala V. Staron A, et al. Blood Adv. 2020 Mar 10;4(5):880-884. doi: 10.1182/bloodadvances.2019001331. Blood Adv. 2020. PMID: 32130406 Free PMC article. Clinical Trial.

6

A pharmacist's review of the treatment of systemic light chain amyloidosis.

Hughes DM, Staron A, Sanchorawala V. Hughes DM, et al. Among authors: staron a. J Oncol Pharm Pract. 2021 Jan;27(1):187-198. doi: 10.1177/1078155220963534. Epub 2020 Oct 7. J Oncol Pharm Pract. 2021. PMID: 33028132 Review.

7

Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities.

Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Staron A, et al. Blood Cancer J. 2020 Nov 10;10(11):118. doi: 10.1038/s41408-020-00385-0. Blood Cancer J. 2020. PMID: 33173025 Free PMC article.

8

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.

Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, Sanchorawala V. Staron A, et al. Blood Cancer J. 2021 Aug 4;11(8):139. doi: 10.1038/s41408-021-00529-w. Blood Cancer J. 2021. PMID: 34349108 Free PMC article. Clinical Trial.

9

Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis.

Staron A, Verma K, Sanchorawala V. Staron A, et al. Br J Haematol. 2022 Sep;198(5):861-865. doi: 10.1111/bjh.18225. Epub 2022 May 2. Br J Haematol. 2022. PMID: 35499208

10

Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.

Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Gustine JN, et al. Among authors: staron a. Am J Hematol. 2022 Sep;97(9):1189-1199. doi: 10.1002/ajh.26641. Epub 2022 Jul 5. Am J Hematol. 2022. PMID: 35731907 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters